Success Metrics

Clinical Success Rate
94.3%

Based on 33 completed trials

Completion Rate
94%(33/35)
Active Trials
1(2%)
Results Posted
21%(7 trials)
Terminated
2(4%)

Phase Distribution

Ph phase_3
8
17%
Ph not_applicable
5
11%
Ph phase_4
18
39%
Ph phase_2
8
17%
Ph phase_1
4
9%

Phase Distribution

4

Early Stage

8

Mid Stage

26

Late Stage

Phase Distribution43 total trials
Phase 1Safety & dosage
4(9.3%)
Phase 2Efficacy & side effects
8(18.6%)
Phase 3Large-scale testing
8(18.6%)
Phase 4Post-market surveillance
18(41.9%)
N/ANon-phased studies
5(11.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.8%

33 of 38 finished

Non-Completion Rate

13.2%

5 ended early

Currently Active

1

trials recruiting

Total Trials

46

all time

Status Distribution
Active(1)
Completed(33)
Terminated(5)
Other(7)

Detailed Status

Completed33
unknown7
Withdrawn3
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
46
Active
1
Success Rate
94.3%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (9.3%)
Phase 28 (18.6%)
Phase 38 (18.6%)
Phase 418 (41.9%)
N/A5 (11.6%)

Trials by Status

terminated24%
unknown715%
withdrawn37%
recruiting12%
completed3372%

Recent Activity

Clinical Trials (46)

Showing 20 of 46 trialsScroll for more
NCT07370532Phase 2

Etoricoxib in Patients With Parkinsonian Disease

Recruiting
NCT06001112Not Applicable

Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis

Completed
NCT01327638

Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

Completed
NCT02503839Phase 1

Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic

Completed
NCT01077843

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Completed
NCT01685424

Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)

Completed
NCT01429168Phase 4

A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)

Withdrawn
NCT04565600Phase 2

Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib

Completed
NCT00264147Phase 2

Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)

Completed
NCT01462370Phase 3

Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)

Completed
NCT00945035Phase 1

Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)

Completed
NCT00757627Phase 4

Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

Completed
NCT01067430Phase 4

Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)

Withdrawn
NCT03011905Phase 3

Rebound Pain After Operations for Distal Radius Fractures With a Volar Plate in Brachial Plexus Block

Completed
NCT04462666Phase 2

Oral Huzhang Granules for Acute Gouty Arthritis

Unknown
NCT04144101Phase 4

Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis

Completed
NCT01190722Phase 4

A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain

Withdrawn
NCT02954484Phase 3

Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty

Completed
NCT01300780Not Applicable

Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching

Completed
NCT01269515Phase 2

Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients

Completed

Drug Details

Intervention Type
DRUG
Total Trials
46